Welcome to the e-CCO Library!

P543: Higher post-induction infliximab serum trough levels are associated with healing of fistulising perianal Crohn’s disease in children
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. El-Matary1*, T. Walters2, H. Huynh3, J. deBruyn4, D. Mack5, K. Jacobson6, M. Sherlock7, P. Church2, E. Wine3, M. Carroll3, E. Benchimol5, S. Lawrence6, A. Griffiths2

Created: Thursday, 21 February 2019, 9:14 AM
P543: Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice – Results of a nationwide, prospective, multicenter study in Germany (MUCUS)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BaumgartMD PhD MBA, D.C.(1)*;Stallmach, A.(2);Schubert, A.(3);Howaldt, S.(4);von Arnim, U.(5);Ochsenkühn, T.(6);Stein, J.(7);Lügering, A.(8);Schmidt, D.(9);Schulz, M.(10);Fischer, A.(10);
Created: Friday, 14 July 2023, 11:05 AM
P543: Point-of-care testing in therapeutic drug monitoring of infliximab
Year: 2022
Source: ECCO'22
Authors: Šahinović, I.(1);Orsic Fric, V.(2);Konjik, V.(3);Pavela, J.(4);Borzan, V.(5);Šerić, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P543: Seven-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Cassieri*1, R. Pica2, E. V. Avallone1, G. Brandimarte3, M. Zippi2, P. Crispino1, D. De Nitto2, P. G. Lecca3, P. Vernia1, P. Paoluzi1, E. S. Corazziari1

Created: Friday, 22 February 2019, 9:41 AM
P543: Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McCartney S.*1, Lindsay J.2, Russell R.3, Gaya D.3, Shaw I.4, Murray C.5, Finney-Hayward T.6, Sebastian S.7

Created: Wednesday, 20 February 2019, 10:36 AM
P543: The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Regev, S.(1);Goren, G.(1);Schwartz, D.(2);Sergienko , R.(3);Friger, M.(4);Nemirovsky , A.(5);Greenberg, D.(6);Monsonego, A.(7);Sarid, O.(1);Slonim-Nevo, V.(1);Odes, S..(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Torres-Rodriguez1, F. Cañete1,2, M. Calafat1, R. Sánchez-Aldehuelo3, M. Rivero4,5, M. Iborra2,6, M. González-Vivo7, I. Vera8, L. de Castro9, L. Bujanda2,10,11,12, M. Barreiro-de Acosta13, X. Calvet2,14, J.M. Benítez15,16, M. Llorente17, G. Surís18, L. Arias-García19, M. David20, A. Castaño-García21, F.J. Garcia-Alonso22, L. Rufo23, J.A. Ferrer24, P. Camo25, J.P. Gisbert2,26, J.M. Huguet27, R. Pajares28, V. Morales29, J. Llaó30, A. Rodríguez31, C. Rodríguez32, M. Navarro33, F. Gomollón2,34, M. Carrillo-Palau35, E. Sesé36, P. Almela37, P. Ramírez de la Piscina38, I. Rodríguez-Lago39, M. Papo40, M. Vela41, M. Mañosa1,2, E. Domènech1,2, on behalf of the Eneida-GETECCU investigators

Created: Thursday, 30 January 2020, 10:12 AM
P544: Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

Created: Wednesday, 20 February 2019, 10:36 AM
P544: Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.G. Feagan1*, W.J. Sandborn2, G. D'Haens3, R.K. Pai4, S.B. Hanauer5, D.C. Wolf6, S. Vermeire7, S. Ghosh8, B.G. Levesque9, K. Shan9, R. Aranda9, W.J. Liu9, A. Olson9

Created: Thursday, 21 February 2019, 9:14 AM
P544: Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Hastier-De Chelle*1, V. Cluzeau1, J. Condat1, N. Arab1, X. Hébuterne1, J. Filippi1

Created: Friday, 22 February 2019, 9:41 AM
P544: Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jessen, B.(1);Tóth, M.(1)*;Freise, I.(1);Staudacher, J.(1);Haag, L.M.(1);Kredel, L.(1);Schumann, M.(1);Weidinger, C.(1);Sonnenberg, E.(1);Siegmund, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P544: Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials
Year: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Beaton, M.(2);Bossuyt, P.(3);Dotan, I.(4);Sands, B.(5);Sugimoto, K.(6);Neimark, E.(7);Song, A.(8);Wallace, K.(8);Zhou, Q.(9);Kligys, K.(10);Ferrante, M.(11);
Created: Friday, 11 February 2022, 3:56 PM
P544: Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations
Year: 2021
Source: ECCO'21 Virtual
Authors: Volkers, A.(1);Löwenberg, M.(1);Bray, K.(2);Bahur, B.(2);Braad, M.(1);Abeling, Y.(1);Gecse, K.(1);Duijvestein, M.(1);Ponsioen, C.(1);D'Haens, G.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Calvo Moya1, I. Omella Usieto1, Y. González Lama1, V. Matallana Royo1, I. González Partida1, B. Menchen Viso2, R. De Lucas Téllez de Meneses1, M. González Rodriguez1, P. Bella del Castillo1, M.I. Vera Mendoza1

Created: Thursday, 30 January 2020, 10:12 AM
P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Goncalves1*, M. Santos1, R. Acurcio1, I. Iria1, L. Gouveia1, P. Brito1, A.C. Cunha Santos1, A. Barbas2,3, J. Galvão2, I. Barbosa2, F. Aires da Silva4, A. Alcobia5, M. Cavaco6, M. Cardoso1, J. Delgado Alves7,8, J. Carey9, T. Dorner10, J. Eurico Fonseca6,11, C. Palmela12, J. Torres12, C. Lima Vieira13, D. Trabuco13, G. Fiorino14, A. Strik15, M. Yavzori16, I. Rosa17, L. Correia18, F. Magro19, G. D'Haens15, S. Ben-Horin16, P. Lakatos20,21, S. Danese14

Created: Thursday, 21 February 2019, 9:14 AM
P545: Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab
Year: 2021
Source: ECCO'21 Virtual
Authors: Rubstov, D.(1);Kakkadasam Ramaswamy, P.(1);Edwards, J.(1);Shukla, D.(1);Willmann, L.(1);Moattar, H.(1);Bhullar, M.(1);Ishaq, N.(1);Dorrington, A.(1);Mohsen, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P545: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guerrero Puente L.N.*1, Iglesias Flores E.1, Benítez Cantero J.M.1, Cárdenas Aranzana M.J.2, Medina Medina R.1, Salgueiro Rodríguez I.1, Aguilar Melero P.1, Manzanares Martin B.3, García-Sánchez V.1

Created: Wednesday, 20 February 2019, 10:36 AM
P545: Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pueschel, L.(1);Kockelmann, F.(2);Kueck, M.(3);Tegtbur, U.(3);Seidler, U.(1);Lenzen, H.(1);Attaran-Bandarabadi, M.(4);Bachmann, O.(5);Wedemeyer, H.(1);Wiestler, M.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P545: Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Porcari1, O. Fidanza1, A. Alibrandi2, S. Renna3, M. Cappello4, S. Siringo5, A. Privitera6, G. Inserra7, F. Mocciaro8, G. Magri9, A. Carroccio10, N. Belluardo11, C. Bertolami12, S. Garufi13, M. Ventimiglia3, F. Macaluso3, A. Viola1, M. Cottone15, A. Orlando3, W. Fries*16

Created: Friday, 22 February 2019, 9:41 AM
P545: Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1);Gutiérrez, A.(2);Calviño-Suárez, C.(3); Huguet, J.M.(4);Calvo, M.(5);Aguas, M.(6);Camargo Camero, R.(7);de Jorge Turrión, M.Á.(8);Hervías Cruz, D.(9);López Serrano, P.(10);Marín Pedrosa, S.(11);Martínez Montiel, P.(12);Rivero, M.(13);Vicente Lidón, R.(14);Arias García, L.(15);Arroyo, M.(16);Bujanda, L.(17); Casanova, M.J.(1);Figueiras, M.(18);Lucendo, A.J.(19);Manceñido Marcos, N.(20);Márquez, L.(21);Martín-Arranz, M.D.(22);Boscá Watts, M.(23);Ber, Y.(24);Ramírez de la Piscina Urraca, P.(25);Pérez-Martínez, I.(26);Robles, V.(27);Ruiz-Cerulla, A.(28);Vázquez Morón, J.M.(29);Madero, L.(2);Barreiro-de Acosta, M.(3);Capilla, M.(4);Vera Mendoza, I.(5);Acosta, D.(1);Brenes, Y.(1);Hermida, S.(1);Parra, P.(1);G. Donday, M.(1); Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM